BioCentury | Jun 24, 2020
Finance

Expect more company creation by BGV with its €105M fourth fund

BioGeneration Ventures is the latest in a string of European early-stage VCs raising upsized funds that give them the ability to commit more capital to portfolio companies and retain larger stakes longer. The firm also...
BioCentury | Jun 13, 2020
Management Tracks

Sawyers to head AACR next year; plus Quell, CalciMedica, Bigfoot, Celyad, Praxis, Affimed and more

The American Association for Cancer Research elected Charles Sawyers as president; he will assume the role during AACR’s 2021 meeting, which will take place in Washington on April 9-14. Sawyers is chair of Memorial Sloan...
BioCentury | May 7, 2019
Finance

Confo’s €30M growth plan

Two pharma deals and early preclinical data from Confo’s GPCR-modulating compounds persuaded BioGeneration and Wellington to make their first investments in a company targeting G protein-coupled receptors. A €30 million ($33.6 million) series A round,...
BioCentury | Dec 11, 2018
Company News

Management tracks: Grail, EUSA

Cancer detection company Grail Inc. (Menlo Park, Calif.) appointed Catherine Friedman chairman. She succeeds Bill Rastetter, who will continue as a director. Friedman joined Grail's board last year and also serves on the board of...
BioCentury | Oct 12, 2018
Emerging Company Profile

Targeting GPCRs, Ab Initio

Ab Initio Biotherapeutics Inc. is using its biochemistry expertise and an integrated set of three platforms to purify GPCRs in clinically relevant conformations for producing anti-GPCR antibodies. Antibodies can act on their targets with better...
BioCentury | Dec 22, 2017
Company News

Confo in GPCRs deals with Roche, Lundbeck

Confo Therapeutics N.V. (Brussels, Belgium) granted Roche (SIX:ROG; OTCQX:RHHBY) exclusive, worldwide rights to its small molecule agonists against an undisclosed GPCR. Confo will receive a total of €6 million ($7.1 million) over 30 months, including...
BioCentury | Dec 19, 2017
Company News

Confo, Roche in GPCR deal

Confo Therapeutics N.V. (Brussels, Belgium) granted Roche (SIX:ROG; OTCQX:RHHBY) exclusive, worldwide rights to its small molecule agonists against an undisclosed GPCR. Confo will receive a total of €6 million ($7.1 million) over 30 months, including...
BioCentury | May 25, 2017
Finance

Europe’s translational springtime

European science is showing early signs of translational growth, with VCs increasingly shifting their focus to preclinical assets. But investors are concerned the region still doesn’t have the supply of management talent or funding it...
BioCentury | Mar 10, 2017
Company News

Management tracks

Orphan disease company Dynacure S.A.S. (Illkirch-Graffenstaden, France) named Stephane van Rooijen CEO and Frederic Legros COO. van Rooijen was CEO at Confo Therapeutics N.V. (Brussels, Belgium). Legros was VP and corporate head of business development...
BioCentury | Dec 2, 2016
Financial News

V-Bio closes EUR 76M fund

V-Bio Ventures closed its first life sciences fund at EUR 76 million ($81 million). LPs include the European Investment Fund (EIF), PMV-ARKimedes, Korys, KU Leuven, Gimv, SFPI-FPIM, BNP Paribas Fortis Private Equity and Ghent University...
Items per page:
1 - 10 of 16
BioCentury | Jun 24, 2020
Finance

Expect more company creation by BGV with its €105M fourth fund

BioGeneration Ventures is the latest in a string of European early-stage VCs raising upsized funds that give them the ability to commit more capital to portfolio companies and retain larger stakes longer. The firm also...
BioCentury | Jun 13, 2020
Management Tracks

Sawyers to head AACR next year; plus Quell, CalciMedica, Bigfoot, Celyad, Praxis, Affimed and more

The American Association for Cancer Research elected Charles Sawyers as president; he will assume the role during AACR’s 2021 meeting, which will take place in Washington on April 9-14. Sawyers is chair of Memorial Sloan...
BioCentury | May 7, 2019
Finance

Confo’s €30M growth plan

Two pharma deals and early preclinical data from Confo’s GPCR-modulating compounds persuaded BioGeneration and Wellington to make their first investments in a company targeting G protein-coupled receptors. A €30 million ($33.6 million) series A round,...
BioCentury | Dec 11, 2018
Company News

Management tracks: Grail, EUSA

Cancer detection company Grail Inc. (Menlo Park, Calif.) appointed Catherine Friedman chairman. She succeeds Bill Rastetter, who will continue as a director. Friedman joined Grail's board last year and also serves on the board of...
BioCentury | Oct 12, 2018
Emerging Company Profile

Targeting GPCRs, Ab Initio

Ab Initio Biotherapeutics Inc. is using its biochemistry expertise and an integrated set of three platforms to purify GPCRs in clinically relevant conformations for producing anti-GPCR antibodies. Antibodies can act on their targets with better...
BioCentury | Dec 22, 2017
Company News

Confo in GPCRs deals with Roche, Lundbeck

Confo Therapeutics N.V. (Brussels, Belgium) granted Roche (SIX:ROG; OTCQX:RHHBY) exclusive, worldwide rights to its small molecule agonists against an undisclosed GPCR. Confo will receive a total of €6 million ($7.1 million) over 30 months, including...
BioCentury | Dec 19, 2017
Company News

Confo, Roche in GPCR deal

Confo Therapeutics N.V. (Brussels, Belgium) granted Roche (SIX:ROG; OTCQX:RHHBY) exclusive, worldwide rights to its small molecule agonists against an undisclosed GPCR. Confo will receive a total of €6 million ($7.1 million) over 30 months, including...
BioCentury | May 25, 2017
Finance

Europe’s translational springtime

European science is showing early signs of translational growth, with VCs increasingly shifting their focus to preclinical assets. But investors are concerned the region still doesn’t have the supply of management talent or funding it...
BioCentury | Mar 10, 2017
Company News

Management tracks

Orphan disease company Dynacure S.A.S. (Illkirch-Graffenstaden, France) named Stephane van Rooijen CEO and Frederic Legros COO. van Rooijen was CEO at Confo Therapeutics N.V. (Brussels, Belgium). Legros was VP and corporate head of business development...
BioCentury | Dec 2, 2016
Financial News

V-Bio closes EUR 76M fund

V-Bio Ventures closed its first life sciences fund at EUR 76 million ($81 million). LPs include the European Investment Fund (EIF), PMV-ARKimedes, Korys, KU Leuven, Gimv, SFPI-FPIM, BNP Paribas Fortis Private Equity and Ghent University...
Items per page:
1 - 10 of 16